Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer

Breast

Volumn 18, Issue 2, 2009, Pages 78-83

  Schwartzberg, Lee S ^a   Cobb, Patrick ^a   Senecal, Frank ^a   Henry, David ^a   Kulig, Kimary ^b   Walker, Mark S ^a   Houts, Arthur C ^a   Stepanski, Edward J ^a  

^a Accelerated Community Oncology Research Network   (United States)

^b PFIZER INC   (United States)

Author keywords

Adverse events; Aromatase inhibitor; Endocrine therapy; Switch discontinue treatment; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CARDIOVASCULAR SYMPTOM; COGNITIVE DEFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MYALGIA; NIGHT SWEAT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; STRUCTURED INTERVIEW; VASOMOTOR DISORDER;

EID: 64649099757     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.01.002     Document Type: Article

References (22)

1. Arora A., and Potter J.F. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J Am Geriatr Soc 52 4 (2004) 611-616
2. Ponzone R., Biglia N., Jacomuzzi M.E., Mariani L., Dominguez A., and Sismondi P. Antihormones in prevention and treatment of breast cancer. Ann N Y Acad Sci 1089 (2006) 143-158
3. Buzdar A.U. Anastrozole (arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther 2 6 (2002) 623-629
4. Patel R.R., Sharma C.G., and Jordan V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14 2 (2007) 113-122
5. Mauri D., Pavlidis N., Polyzos N.P., and Ioannidis J.P. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98 18 (2006) 1285-1291
6. Joensuu H., Ejlertsen B., Lonning P.E., and Rutqvist L.E. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol 44 1 (2005) 23-31
7. Baum M., Buzdar A.U., Cuzick J., Forbes J., Houghton JH., Klijn JG., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
8. Buzdar A., Chlebowski R., Cuzick J., Duffy S., Forbes J., Jonat W., et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 22 8 (2006) 1575-1585
9. Buzdar A.U., Guastalla J.P., Nabholtz J.M., Cuzick J., and Group A.T. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (anastrozole and tamoxifen, alone or in combination) trial. Cancer 107 3 (2006) 472-480
10. Monnier A.M. The Breast International Group 1-98 trial: BIG results for women with hormone-sensitive early breast cancer. Expert Rev Anticancer Ther 7 5 (2007) 627-634
11. Forbes J.F. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Semin Oncol 33 2 Suppl. 7 (2006) S2-S7
12. Jones S.E. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer 6 Suppl. 2 (2006) S41-S44
13. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25 19 (2007) 2664-2670
14. Goss P.E., Ingle J.N., Martino S., Robert NJ., Muss HB., Piccart MJ., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25 15 (2007) 2006-2011
15. Spicer J., and Ellis P. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition. Cancer Lett 248 2 (2007) 165-174
16. Winer E.P., Hudis C., Burstein H.J., Wolff AC., Pritchard KI., Ingle JN., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 3 (2005) 619-629
17. Lonning P.E. Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 16 Suppl. 2 (2006) 518-520
18. Morales L., Neven P., Timmerman D., Christiaens MR., Vergote I., Van Limbergen E., et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15 8 (2004) 753-760
19. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98 9 (2003) 1802-1810
20. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Washington, D.C.; 2003.
21. Buzdar A., Howell A., Cuzick J., Wale C., Distler W., Hoctin-Boes G., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 8 (2006) 633-643
22. Partridge A.H., LaFountain A., Mayer E., Taylor B.S., Winer E., and Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26 4 (2008) 556-562